When is an Impella left‑ventricular assist device indicated for an adult with severe left‑ventricular dysfunction (ejection fraction <30%) in cardiogenic shock, and what are its contraindications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Impella Device for Severe LV Dysfunction in Cardiogenic Shock

The Impella device is indicated for adults with severe LV dysfunction (EF <30%) who develop cardiogenic shock, specifically in two primary scenarios: (1) myocardial infarction complicated by cardiogenic shock, and (2) high-risk percutaneous coronary interventions requiring hemodynamic support. 1

Primary Indications

The Impella serves as temporary mechanical circulatory support when patients progress beyond what intra-aortic balloon pump (IABP) and vasopressors can manage. The device selection depends on the degree of support needed:

  • Impella 2.5: Provides up to 2.5 L/min flow via percutaneous femoral insertion across the aortic valve. This is FDA-approved for high-risk coronary angioplasty and MI-related cardiogenic shock 1

  • Impella 5.0/5.5: Delivers 5-5.5 L/min flow but requires surgical arterial cut-down for insertion. Use this for patients with larger body mass index or those requiring higher flow rates 1

Critical caveat: While Impella provides superior hemodynamic support compared to IABP (improved cardiac index, blood pressure, and mixed venous oxygen saturation), it has not demonstrated mortality benefit in head-to-head comparisons 1. The device should be viewed as a bridge—to recovery, to durable device, to transplantation, or to definitive cardiac surgery 2.

When to Deploy Impella

Use invasive hemodynamic assessment to guide device selection. Deploy Impella when:

  • Cardiac index remains <2.2 L/min/m² despite maximal medical therapy
  • Evidence of end-organ hypoperfusion persists (elevated lactate, declining urine output, altered mental status)
  • IABP plus inotropes/vasopressors fail to restore adequate perfusion
  • Patient requires high-risk PCI with severe LV dysfunction where hemodynamic collapse is anticipated 3

The key is early recognition and deployment—waiting until SCAI Stage E (extremis) significantly worsens outcomes 4, 2.

Absolute Contraindications

Do not use Impella in patients with:

  • Mechanical aortic valve (device crosses the valve)
  • Severe aortic stenosis or regurgitation (device cannot function properly)
  • LV thrombus (risk of embolization)
  • Ventricular septal defect (worsens shunt)
  • Severe peripheral arterial disease preventing arterial access
  • Aortic dissection

Major Complications to Anticipate

Impella carries significantly higher complication rates than IABP or medical therapy alone:

  • Major bleeding: 3-fold increased risk 5
  • Peripheral limb ischemia: 2.5-fold increased risk 5
  • Thrombosis at the insertion site 1
  • Hemolysis from the axial pump mechanism 2

Monitor for these complications aggressively—check distal pulses, limb perfusion, and hemolysis markers (LDH, haptoglobin, plasma-free hemoglobin) daily.

Device Selection Algorithm

For cardiogenic shock with EF <30%:

  1. Calculate required cardiac output: Use direct Fick method or thermodilution via pulmonary artery catheter 3

  2. If patient needs ≤2.5 L/min support AND has normal BMI: Consider Impella 2.5 (percutaneous, rapid deployment in cath lab)

  3. If patient needs >2.5 L/min support OR has elevated BMI: Use Impella 5.0/5.5 (requires surgical cut-down but provides adequate flow) 1

  4. If isolated RV failure dominates: Consider Impella RP instead, or if pulmonary hypertension is the primary driver, VA-ECMO may be more appropriate 3

Weaning Strategy

Always evaluate for ventricular recovery, particularly in postcardiotomy shock, acute MI, or myocarditis 1. Assess:

  • Serial echocardiography showing improved LVEF
  • Hemodynamic parameters improving (cardiac index >2.2 L/min/m² with device flow reduced)
  • Resolution of end-organ dysfunction (lactate normalizing, urine output adequate, mental status clear)

Wean by progressively reducing device flow while monitoring hemodynamics and clinical parameters 1.

Evidence Limitations

The mortality data remains disappointing—no randomized trial has shown survival benefit with Impella over IABP or medical therapy in cardiogenic shock 5. The device provides better hemodynamics but at the cost of substantially higher bleeding and vascular complications. Current evidence suggests Impella is best reserved for carefully selected patients as a bridge strategy rather than as definitive therapy expected to reduce mortality 5.

Ongoing randomized controlled trials are critical to better define which patients benefit most from Impella support 4, 2. Until then, use Impella judiciously in patients who have a realistic bridge destination (recovery, durable LVAD, transplant, or corrective surgery) and acceptable vascular access.

References

Related Questions

What are the indications and uses for Impella (Intra-Aortic Balloon Pump) devices in patients with heart failure or cardiogenic shock?
What is an Impella mechanical circulatory support device?
How should I evaluate a patient with cardiogenic shock?
What is an acceptable measured blood pressure at the arterial line for a patient on Impella (Intra-Aortic Balloon Pump) CP (Cardiac Power) support?
Should a patient with severe cardiogenic shock (cardiac output 2.5 L/min, cardiac index 1.5 L/min/m²) be admitted despite being alert and oriented ×4?
What are the local complications of pancreatitis?
How often should lacosamide (Vimpat) serum levels be checked?
Is it safe to co‑prescribe nonsteroidal anti‑inflammatory drugs (NSAIDs) with Wellbutrin (bupropion) or pregabalin, and what precautions are needed?
What adverse effects might a 30 mg dose of ulipristal acetate cause in a patient with anticholinergic syndrome and elevated inflammatory markers?
What is the recommended frequency for nasal saline irrigation in healthy infants?
How should I manage a 78-year-old woman with mild adult acne that flares with stress, who discontinued azelaic acid 20% topical cream, intermittently uses a relative's tretinoin cream, and previously experienced reflux with an oral antibiotic, now resumed omeprazole?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.